Russell Frank Company’s Rigel Pharmaceuticals RIGL Stock Holding History

Russell Frank Company’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$460K	Hold	22,131	–	–	﹤0.01%	2482
2015 Q4	$677K	Buy	22,131 +492	+2%	+$14.9K	﹤0.01%	2383
2015 Q3	$535K	Sell	21,639 -4,962	-19%	-$148K	﹤0.01%	2450
2015 Q2	$854K	Buy	26,601 +9,081	+52%	+$347K	﹤0.01%	2387
2015 Q1	$626K	Sell	17,520 -4,073	-19%	-$112K	﹤0.01%	2336
2014 Q4	$488K	Buy	21,593 +4,390	+26%	+$88.8K	﹤0.01%	2405
2014 Q3	$334K	Buy	17,203 +3,560	+26%	+$101K	﹤0.01%	2436
2014 Q2	$444K	Sell	13,643 -6,126	-31%	-$208K	﹤0.01%	2362
2014 Q1	$638K	Sell	19,769 -3,361	-15%	-$120K	﹤0.01%	2286
2013 Q4	$709K	Buy	23,130 +8,357	+57%	+$245K	﹤0.01%	2212
2013 Q3	$528K	Buy	14,773 +8,251	+127%	+$301K	﹤0.01%	2472
2013 Q2	$217K	Buy	+6,522	New	+$296K	﹤0.01%	2562

Other funds holding RIGL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Russell Frank Company's RIGL Position: Q1 2016 in Review

Russell Frank Company held its Rigel Pharmaceuticals (RIGL) position steady in Q1 2016 at 22,131 shares worth $460K. The position accounts for ﹤0.01% of the portfolio, ranked #2482.

Russell Frank Company first reported a position in RIGL in Q2 2013 and has held it in 12 quarters since. The position peaked at $854K in Q2 2015. 120 funds tracked by Wall St. Rank hold RIGL as of Q1 2016.

Russell Frank Company held 22,131 shares of Rigel Pharmaceuticals worth $460K as of Q1 2016.
Russell Frank Company left its Rigel Pharmaceuticals share count unchanged in Q1 2016.
Rigel Pharmaceuticals made up ﹤0.01% of Russell Frank Company's portfolio in Q1 2016, its #2482 holding.
Russell Frank Company first reported a position in Rigel Pharmaceuticals in Q2 2013 and has held it in 12 quarters since.
Russell Frank Company's Rigel Pharmaceuticals position peaked at $854K in Q2 2015.
120 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.